Jim Cramer Shed Light on These 9 Stocks

2. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders: 61

A caller asked Cramer about Novo Nordisk A/S (NYSE:NVO) and how it compares to Eli Lilly and Cramer replied:

“Okay, Novo Nordisk I think is inferior. They don’t have the production capability. They don’t have what I think is the best pipeline. And I gotta tell you, Denmark, geez, maybe president-elect Trump’s gonna pick a fight with them. I’d be careful.”

Novo Nordisk A/S (NYSE:NVO) is involved in researching, developing, producing, and distributing pharmaceutical products. Over the past year, NVO stock is down more than 20% while LLY stock has gained over 24%.

ClearBridge Investments stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its Q4 2024 investor letter:

“Similarly, we used a temporary price dislocation caused by disappointing clinical trial results to purchase shares of Novo Nordisk A/S (NYSE:NVO), a Danish-based leader in diabetes and obesity treatments. Novo’s Wegovy semaglutide drug was first to market among the new generation of obesity drugs; however, the company has lost market share to portfolio holding Eli Lilly due to delays in scaling up production volumes and superior weight loss results demonstrated by Lilly’s trizepatide drugs. While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite. With Novo poised to have a better product portfolio and improved supply position, we find the company’s valuation very attractive given the large secular growth trends behind the diabesity market.”